Improved antibody pharmacokinetics by disruption of contiguous positive surface potential and charge reduction using alternate human framework

References

• Ju MS, Jung ST. Antigen design for successful isolation of highly challenging therapeutic anti-GPCR antibodies. Int J Mol Sci. 2020;21:8240. doi:10.3390/ijms21218240. PMID: 33153215.
   PubMed Web of Science ®Google Scholar
• Plotkin SS, Cashman NR. Passive immunotherapies targeting Abeta and tau in Alzheimer’s disease. Neurobiol Dis. 2020;144:105010. doi:10.1016/j.nbd.2020.105010. PMID: 32682954.
   PubMed Web of Science ®Google Scholar
• Lyu X, Zhao Q, Hui J, Wang T, Lin M, Wang K, Zhang J, Shentu J, Dalby PA, Zhang H, et al. The global landscape of approved antibody therapies. Antib Ther. 2022;5(4):233–13. doi:10.1093/abt/tbac021. PMID: 36213257.
   PubMedGoogle Scholar
• Townsend S, Fennell BJ, Apgar JR, Lambert M, McDonnell B, Grant J, Wade J, Franklin E, Foy N, Ni Shuilleabhain D, et al. Augmented binary substitution: single-pass CDR germ-lining and stabilization of therapeutic antibodies. Proc Natl Acad Sci U S A. 2015;112(50):15354–59. doi:10.1073/pnas.1510944112. PMID: 26621728.
   PubMed Web of Science ®Google Scholar
• Li B, Tesar D, Boswell CA, Cahaya HS, Wong A, Zhang J, Meng YG, Eigenbrot C, Pantua H, Diao J, et al. Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge. MAbs. 2014;6(5):1255–64. doi:10.4161/mabs.29809. PMID: 25517310.
   PubMed Web of Science ®Google Scholar
• Ewert S, Honegger A, Pluckthun A. Stability improvement of antibodies for extracellular and intracellular applications: cDR grafting to stable frameworks and structure-based framework engineering. Methods. 2004;34(2):184–99. PMID: 15312672. doi:10.1016/j.ymeth.2004.04.007.
   PubMed Web of Science ®Google Scholar
• Kugler M, Stein C, Schwenkert M, Saul D, Vockentanz L, Huber T, Wetzel SK, Scholz O, Pluckthun A, Honegger A, et al. Stabilization and humanization of a single-chain Fv antibody fragment specific for human lymphocyte antigen CD19 by designed point mutations and CDR-grafting onto a human framework. Protein Eng Des Sel. 2009;22:135–47. doi:10.1093/protein/gzn079. PMID: 19188138.
   PubMed Web of Science ®Google Scholar
• Finlay WJ, Cunningham O, Lambert MA, Darmanin-Sheehan A, Liu X, Fennell BJ, Mahon CM, Cummins E, Wade JM, O’Sullivan CM, et al. Affinity maturation of a humanized rat antibody for anti-RAGE therapy: comprehensive mutagenesis reveals a high level of mutational plasticity both inside and outside the complementarity-determining regions. J Mol Biol. 2009;388:541–58. doi:10.1016/j.jmb.2009.03.019. PMID: 19285987.
   PubMed Web of Science ®Google Scholar
• Yu YJ, Watts RJ. Developing therapeutic antibodies for neurodegenerative disease. Neurotherapeutics. 2013;10(3):459–72. PMID: 23549647. doi:10.1007/s13311-013-0187-4.
   PubMed Web of Science ®Google Scholar
• Tang Y, Cao Y. Modeling pharmacokinetics and pharmacodynamics of therapeutic antibodies: progress, challenges, and future directions. Pharmaceutics. 2021;13(3):422. PMID: 33800976. doi:10.3390/pharmaceutics13030422.
   PubMed Web of Science ®Google Scholar
• Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7(9):715–25. PMID: 17703228. doi:10.1038/nri2155.
   PubMed Web of Science ®Google Scholar
• Dall’acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem. 2006;281:23514–24. doi:10.1074/jbc.M604292200. PMID: 16793771.
   PubMed Web of Science ®Google Scholar
• Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, Sproule TJ, Lazar GA, Roopenian DC, Desjarlais JR. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol. 2010;28(2):157–59. PMID: 20081867. doi:10.1038/nbt.1601.
   PubMed Web of Science ®Google Scholar
• Roopenian DC, Christianson GJ, Sproule TJ. Human FcRn transgenic mice for pharmacokinetic evaluation of therapeutic antibodies. Methods Mol Biol. 2010;602:93–104. doi:10.1007/978-1-60761-058-8_6. PMID: 20012394.
   PubMedGoogle Scholar
• Avery LB, Wang M, Kavosi MS, Joyce A, Kurz JC, Fan YY, Dowty ME, Zhang M, Zhang Y, Cheng A, et al. Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies. MAbs. 2016;8(6):1064–78. doi:10.1080/19420862.2016.1193660. PMID: 27232760.
   PubMed Web of Science ®Google Scholar
• Dobson CL, Devine PWA, Phillips JJ, Higazi DR, Lloyd C, Popovic B, Arnold J, Buchanan A, Lewis A, Goodman J, et al. Engineering the surface properties of a human monoclonal antibody prevents self-association and rapid clearance in vivo. Sci Rep. 2016; (1):6. doi:10.1038/srep38644.
   PubMedGoogle Scholar
• Leipold D, Prabhu S. Pharmacokinetic and pharmacodynamic considerations in the design of therapeutic antibodies. Clin Transl Sci. 2019;12(2):130–39. PMID: 30414357. doi:10.1111/cts.12597.
   PubMed Web of Science ®Google Scholar
• Schoch A, Kettenberger H, Mundigl O, Winter G, Engert J, Heinrich J, Emrich T. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proc Natl Acad Sci U S A. 2015;112:5997–6002. doi:10.1073/pnas.1408766112. PMID: 25918417.
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A, Thangaraju A, Leung D, Tang Y, Witcher DR, Lu J, Wroblewski VJ. Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics. MAbs. 2015;7(3):483–93. PMID: 25695748. doi:10.1080/19420862.2015.1016696.
   PubMed Web of Science ®Google Scholar
• Hotzel I, Theil FP, Bernstein LJ, Prabhu S, Deng R, Quintana L, Lutman J, Sibia R, Chan P, Bumbaca D, et al. A strategy for risk mitigation of antibodies with fast clearance. MAbs. 2012;4(6):753–60. doi:10.4161/mabs.22189. PMID: 23778268.
   PubMed Web of Science ®Google Scholar
• Dostalek M, Prueksaritanont T, Kelley RF. Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates. MAbs. 2017;9(5):756–66. PMID: 28463063. doi:10.1080/19420862.2017.1323160.
   PubMed Web of Science ®Google Scholar
• Kelly RL, Sun T, Jain T, Caffry I, Yu Y, Cao Y, Lynaugh H, Brown M, Vasquez M, Wittrup KD, et al. High throughput cross-interaction measures for human IgG1 antibodies correlate with clearance rates in mice. MAbs. 2015;7(4):770–77. doi:10.1080/19420862.2015.1043503. PMID: 26047159.
   PubMed Web of Science ®Google Scholar
• Sharma VK, Patapoff TW, Kabakoff B, Pai S, Hilario E, Zhang B, Li C, Borisov O, Kelley RF, Chorny I, et al. In silico selection of therapeutic antibodies for development: viscosity, clearance, and chemical stability. Proc Natl Acad Sci U S A. 2014;111:18601–06. doi:10.1073/pnas.1421779112. PMID: 25512516.
   PubMed Web of Science ®Google Scholar
• Avery LB, Wade J, Wang M, Tam A, King A, Piche-Nicholas N, Kavosi MS, Penn S, Cirelli D, Kurz JC, et al. Establishing in vitro in vivo correlations to screen monoclonal antibodies for physicochemical properties related to favorable human pharmacokinetics. MAbs. 2018;10(2):244–55. doi:10.1080/19420862.2017.1417718. PMID: 29271699.
   PubMed Web of Science ®Google Scholar
• Afroz T, Chevalier E, Audrain M, Dumayne C, Ziehm T, Moser R, Egesipe AL, Mottier L, Ratnam M, Neumann M, et al. Immunotherapy targeting the C-terminal domain of TDP-43 decreases neuropathology and confers neuroprotection in mouse models of ALS/FTD. Neurobiol Dis. 2023;179:106050. doi:10.1016/j.nbd.2023.106050. PMID: 36809847.
   PubMed Web of Science ®Google Scholar
• Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79(3):416–38. PMID: 23931993. doi:10.1016/j.neuron.2013.07.033.
   PubMed Web of Science ®Google Scholar
• Afroz T, Hock EM, Ernst P, Foglieni C, Jambeau M, Gilhespy LAB, Laferriere F, Maniecka Z, Pluckthun A, Mittl P, et al. Functional and dynamic polymerization of the ALS-linked protein TDP-43 antagonizes its pathologic aggregation. Nat Commun. 2017;8(1):45. doi:10.1038/s41467-017-00062-0. PMID: 28663553.
   PubMedGoogle Scholar
• Lukavsky PJ, Daujotyte D, Tollervey JR, Ule J, Stuani C, Buratti E, Baralle FE, Damberger FF, Allain FH. Molecular basis of UG-rich RNA recognition by the human splicing factor TDP-43. Nature Structural & Molecular Biology. 2013;20(12):1443–49. PMID: 24240615. doi:10.1038/nsmb.2698.
   PubMed Web of Science ®Google Scholar
• Ayala YM, Zago P, D’Ambrogio A, Xu YF, Petrucelli L, Buratti E, Baralle FE. Structural determinants of the cellular localization and shuttling of TDP-43. J Cell Sci. 2008;121:3778–85. doi:10.1242/jcs.038950. PMID: 18957508.
   PubMed Web of Science ®Google Scholar
• Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130–33. doi:10.1126/science.1134108. PMID: 17023659.
   PubMed Web of Science ®Google Scholar
• Polymenidou M, Cleveland DW. The seeds of neurodegeneration: prion-like spreading in ALS. Cell. 2011;147(3):498–508. PMID: 22036560. doi:10.1016/j.cell.2011.10.011.
   PubMed Web of Science ®Google Scholar
• Porta S, Xu Y, Restrepo CR, Kwong LK, Zhang B, Brown HJ, Lee EB, Trojanowski JQ, Lee VM. Patient-derived frontotemporal lobar degeneration brain extracts induce formation and spreading of TDP-43 pathology in vivo. Nat Commun. 2018;9(1):4220. PMID: 30310141. doi:10.1038/s41467-018-06548-9.
   PubMedGoogle Scholar
• Kawakami I, Arai T, Hasegawa M. The basis of clinicopathological heterogeneity in TDP-43 proteinopathy. Acta Neuropathol. 2019;138(5):751–70. PMID: 31555895. doi:10.1007/s00401-019-02077-x.
   PubMed Web of Science ®Google Scholar
• Betts A, Keunecke A, van Steeg TJ, van der Graaf PH, Avery LB, Jones H, Berkhout J, van Steeg TJ, van der Graaf PH. Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: a comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach. MAbs. 2018;10(5):751–64. PMID: 29634430. doi:10.1080/19420862.2018.1462429.
   PubMed Web of Science ®Google Scholar
• Kasai T, Kojima Y, Ohmichi T, Tatebe H, Tsuji Y, Noto YI, Kitani-Morii F, Shinomoto M, Allsop D, Mizuno T, et al. Combined use of CSF NfL and CSF TDP-43 improves diagnostic performance in ALS. Ann Clin Transl Neurol. 2019;6(12):2489–502. doi:10.1002/acn3.50943. PMID: 31742901.
   PubMed Web of Science ®Google Scholar
• Liu S, Verma A, Kettenberger H, Richter WF, Shah DK. Effect of variable domain charge on in vitro and in vivo disposition of monoclonal antibodies. MAbs. 2021;13(1):1993769. PMID: 34711143. doi:10.1080/19420862.2021.1993769.
   PubMed Web of Science ®Google Scholar
• Tabrizi M, Bornstein GG, Suria H. Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. Aaps J. 2010;12(1):33–43. PMID: 19924542. doi:10.1208/s12248-009-9157-5.
   PubMed Web of Science ®Google Scholar
• Igawa T, Tsunoda H, Tachibana T, Maeda A, Mimoto F, Moriyama C, Nanami M, Sekimori Y, Nabuchi Y, Aso Y, et al. Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel. 2010;23:385–92. doi:10.1093/protein/gzq009. PMID: 20159773.
   PubMed Web of Science ®Google Scholar
• Bumbaca Yadav D, Sharma VK, Boswell CA, Hotzel I, Tesar D, Shang Y, Ying Y, Fischer SK, Grogan JL, Chiang EY, et al. Evaluating the use of antibody variable region (Fv) Charge as a risk assessment tool for predicting typical cynomolgus monkey pharmacokinetics. J Biol Chem. 2015;290:29732–41. doi:10.1074/jbc.M115.692434. PMID: 26491012.
   PubMed Web of Science ®Google Scholar
• Ober RJ, Radu CG, Ghetie V, Ward ES. Differences in promiscuity for antibody–FcRn interactions across species: implications for therapeutic antibodies. Int Immunol. 2001;13(12):1551–59. PMID: 11717196. doi:10.1093/intimm/13.12.1551.
   PubMed Web of Science ®Google Scholar
• Andersen JT, Daba MB, Berntzen G, Michaelsen TE, Sandlie I. Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding. J Biol Chem. 2010;285:4826–36. doi:10.1074/jbc.M109.081828. PMID: 20018855.
   PubMed Web of Science ®Google Scholar
• Dunbar J, Krawczyk K, Leem J, Marks C, Nowak J, Regep C, Georges G, Kelm S, Popovic B, Deane CM. SAbPred: a structure-based antibody prediction server. Nucleic Acids Res. 2016;44(W1):W474–478. PMID: 27131379. doi:10.1093/nar/gkw361.
   PubMed Web of Science ®Google Scholar
• Eisenberg D, Schwarz E, Komaromy M, Wall R. Analysis of membrane and surface protein sequences with the hydrophobic moment plot. J Mol Biol. 1984;179:125–42. doi:10.1016/0022-2836(84)90309-7. PMID: 6502707.
   PubMed Web of Science ®Google Scholar
• Kozlowski LP. IPC 2.0: prediction of isoelectric point and pKa dissociation constants. Nucleic Acids Res. 2021;49:W285–W92. doi:10.1093/nar/gkab295. PMID: 33905510.
   PubMed Web of Science ®Google Scholar
• Almagro JC, Fransson J. Humanization of antibodies. FBL. 2008;13:1619–33. doi:10.2741/2786.
   Google Scholar
• Jain T, Sun T, Durand S, Hall A, Houston NR, Nett JH, Sharkey B, Bobrowicz B, Caffry I, Yu Y, et al. Biophysical properties of the clinical-stage antibody landscape. Proc Natl Acad Sci U S A. 2017;114:944–49. doi:10.1073/pnas.1616408114. PMID: 28096333.
   PubMed Web of Science ®Google Scholar